type 2 diabetes
Conditions
Interventions
Glimepiride group: Starting dose will be 0.5mg/day or 1mg/day at before breakfast or after breakfast depending on the conditions of patients. Maximum dosage is 6mg/day, and treatment period is for 6 m
Sponsors
Tokyo Medical University The 3rd Department of Internal Medicine
Ryokuseikai Hospital Akishima Hospital Ryokuhuso Hospital Niiza Shiki Chuo general Hospital Nishi Tokyo Chuo general Hospital Toda Chuo general Hospital Ebara Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: OHA naive type 2 diabetic patients with HbA1c 6.5%<=HbA1c<8.0, controlled by Diet and Exercise alone or a-GI mono therapy for more than 3 months.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1) Patients except type 2 diabetic patients. 2) Patients taking Probucol, vitamin E and/or vitamin C. 3) Alcoholic,or heavy drinker. 4) Patients operated malignant and gastro extraction. 5) Patients with serious complications of DM. Nephropathy:*. Retinopathy:** 6) Drug anaphylaxis patient. 7) Pregnant or patients who plan to carry, or currently breast-feeding woman. 8) Patients who were judged inappropriate to participate in this study by the doctor of study director or cooperative *Proteinuria >= 1g/day ** Stage of preproliferative and proliferative retinopaty by Davis classification
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HbA1c | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)FPG, Fasting IRI, Achievement ratio of HbA1c below 6.5%. 2)TC,TG,HDL-C,LDL-C,BW,BMI,HOMA-IR 3)Urinal 8-OHdG, hs-CRP, Adiponectin, High Molecular Weight Adiponectin, High Sensitive TNF-a, TGF-b | — |
Countries
Japan
Contacts
Public ContactTakashi Miwa
Tokyo Medical University The 3rd Department of Internal Medicine
Outcome results
None listed